Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice

Brain Research

Volumn 1188, Issue 1, 2008, Pages 148-156

  Richter, Franziska ^a   Hamann, Melanie ^a   Richter, Angelika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

6 OHDA; Animal model; Dopamine; Movement disorder; Neurodegeneration; Parkinson's disease

Indexed keywords

OXIDOPAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

ANIMALS; CELL COUNT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURONS; NEUROTOXINS; OXIDOPAMINE; PARKINSONIAN DISORDERS; SYMPATHOLYTICS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; MUS;

EID: 37349085745     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.09.083     Document Type: Article

References (50)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec. 94 (1946) 239-247
2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20 (1973) 415-455
3. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 24 (2002) 308-318
4. Blandini F., Levandis G., Bazzini E., Nappi G., and Armentero M.T. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur. J. Neurosci. 25 (2007) 397-405
5. Bove J., Prou D., Perier C., and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2 (2005) 484-494
6. Chesselet M.F. Dopamine and Parkinson's disease: is the killer in the house?. Mol. Psychiatry 8 (2003) 369-370
7. Crawley J.N. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res. 835 (1999) 18-26
8. Cunningham L.A., and Su C. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp. Neurol. 174 (2002) 230-242
9. Deumens R., Blokland A., and Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175 (2002) 303-317
10. Dunnett S.B., Bjorklund A., Schmidt R.H., Stenevi U., and Iversen S.D. Intracerebral grafting of neuronal cell suspensions. V. Behavioural recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions. Acta Physiol. Scand., Suppl. 522 (1983) 39-47
11. Ehrhart J., and Zeevalk G.D. Cooperative interaction between ascorbate and glutathione during mitochondrial impairment in mesencephalic cultures. J. Neurochem. 86 (2003) 1487-1497
12. Glinka Y.Y., and Youdim M.B. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 292 (1995) 329-332
13. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14 (1978) 633-643
14. Hamann M., and Richter A. Effects of striatal injections of GABA(A) receptor agonists and antagonists in a genetic animal model of paroxysmal dystonia. Eur. J. Pharmacol. 443 (2002) 59-70
15. Hamann M., Meisler M.H., and Richter A. Motor disturbances in mice with deficiency of the sodium channel gene Scn8a show features of human dystonia. Exp. Neurol. 184 (2003) 830-838
16. Hedreen J.C., and DeLong M.R. Organization of striatopallidal, striatonigral, and nigrostriatal projections in the macaque. J. Comp. Neurol. 304 (1991) 569-595
17. Hornykiewicz O., and Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45 (1987) 19-34
18. Ichitani Y., Okamura H., Nakahara D., Nagatsu I., and Ibata Y. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra. Exp. Neurol. 130 (1994) 269-278
19. Jackson-Lewis V., Vila M., Djaldetti R., Guegan C., Liberatore G., Liu J., O'Malley K.L., Burke R.E., and Przedborski S. Developmental cell death in dopaminergic neurons of the substantia nigra of mice. J. Comp. Neurol. 424 (2000) 476-488
20. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 (1998) 259-277
21. Kostrzewa R.M., and Jacobowitz D.M. Pharmacological actions of 6-hydroxydopamine. Pharmacol. Rev. 26 (1974) 199-288
22. Lang A.E., and Lozano A.M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 339 (1998) 1130-1143
23. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339 (1998) 1044-1053
24. Le Couteur D.G., Muller M., Yang M.C., Mellick G.D., and McLean A.J. Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease. Rev. Environ. Health 17 (2002) 51-64
25. Lindner M.D., Cain C.K., Plone M.A., Frydel B.R., Blaney T.J., Emerich D.F., and Hoane M.R. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav. Brain Res. 102 (1999) 1-16
26. Lotharius J., Dugan L.L., and O'Malley K.L. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19 (1999) 1284-1293
27. Lundblad M., Picconi B., Lindgren H., and Cenci M.A. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 16 (2004) 110-123
28. Lundblad M., Usiello A., Carta M., Hakansson K., Fisone G., and Cenci M.A. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp. Neurol. 194 (2005) 66-75
29. Maharaj H., Sukhdev Maharaj D., Scheepers M., Mokokong R., and Daya S. l-DOPA administration enhances 6-hydroxydopamine generation. Brain Res. 1063 (2005) 180-186
30. McLaughlin B.A., Nelson D., Erecinska M., and Chesselet M.F. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J. Neurochem. 70 (1998) 2406-2415
31. Meissner W., Hill M.P., Tison F., Gross C.E., and Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol. Sci. 25 (2004) 249-253
32. Paille V., Henry V., Lescaudron L., Brachet P., and Damier P. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov. Disord. 22 (2007) 533-539
33. Paxinos G., and Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates (2001), Academic Press, San Diego Vol.
34. Perez F.A., Curtis W.R., and Palmiter R.D. Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci. 6 (2005) 71
35. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., and Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67 (1995) 631-647
36. Rehders J.H., Loscher W., and Richter A. Evidence for striatal dopaminergic overactivity in paroxysmal dystonia indicated by microinjections in a genetic rodent model. Neuroscience 97 (2000) 267-277
37. Richter F., Hamann M., and Richter A. Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice. J. Neurosci. Res. 85 (2007) 681-691
38. Sander S.E., and Richter A. Striatal microinjections of nitric oxide synthase inhibitors and l-arginine fail to exert effects on paroxysmal dystonia in the dt(sz) mutant. Neurosci. Lett. 398 (2006) 97-101
39. Sauer H., and Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59 (1994) 401-415
40. Scarr E., Wingerchuk D.M., Juorio A.V., and Paterson I.A. The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions. Neurochem. Res. 19 (1994) 153-159
41. Schapira A.H. Science, medicine, and the future: Parkinson's disease. BMJ 318 (1999) 311-314
42. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54 (1990) 823-827
43. Schwarting R.K., and Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50 (1996) 275-331
44. Schwarting R.K., and Huston J.P. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol. 49 (1996) 215-266
45. Seiden L.S., and Vosmer G. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol. Biochem. Behav. 21 (1984) 29-31
46. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5 (1968) 107-110
47. von Bohlen und Halbach O., Schober A., and Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog. Neurobiol. 73 (2004) 151-177
48. Von Voigtlander P.F., and Moore K.E. Turning behavior of mice with unilateral 6-hydroxydopamine lesions in the striatum: effects of apomorphine, L-DOPA, amanthadine, amphetamine and other psychomotor stimulants. Neuropharmacology 12 (1973) 451-462
49. Yuan H., Sarre S., Ebinger G., and Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J. Neurosci. Methods 144 (2005) 35-45
50. Zigmond M.J., and Stricker E.M. Parkinson's disease: studies with an animal model. Life Sci. 35 (1984) 5-18